Podophyllin office therapy against condyloma should be abandoned
- 1Department of Dermatovenereology, Karolinska Hospital, 17176, Stockholm, Sweden
- 2Pre-clinical Development Services Ltd, Stockport, UK
- Dr von Krogh
- Accepted 22 May 2001
Podophyllin, a crude plant extract with low efficacy, high toxicity, and a serious mutagenicity profile does not comply with the WHO guidelines for plant derived treatments and should be removed from clinical treatment protocols. Home treatment with pharmaceutical products based on podophyllotoxin—the purified, standardised active antiwart ingredient of podophyllin—represents safe and effective first line therapy for patients with anogenital warts.